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Lack of Effect of Lowering LDL Cholesterol on Cancer:
Meta-Analysis of Individual Data from 175,000 People in
27 Randomised Trials of Statin Therapy
Cholesterol Treatment Trialists’ (CTT) Collaboration*"
Abstract
Background: Statin therapy reduces the risk of occlusive vascular events, but uncertainty remains about potential effects on
cancer. We sought to provide a detailed assessment of any effects on cancer of lowering LDL cholesterol (LDL-C) with a
statin using individual patient records from 175,000 patients in 27 large-scale statin trials.
Methods and Findings: Individual records of 134,537 participants in 22 randomised trials of statin versus control (median
duration 4.8 years) and 39,612 participants in 5 trials of more intensive versus less intensive statin therapy (median duration
5.1 years) were obtained. Reducing LDL-C with a statin for about 5 years had no effect on newly diagnosed cancer or on
death from such cancers in either the trials of statin versus control (cancer incidence: 3755 [1.4% per year [py]] versus 3738
[1.4% py], RR 1.00 [95% CI 0.96-1.05]; cancer mortality: 1365 [0.5% py] versus 1358 [0.5% py], RR 1.00 [95% CI 0.93–1.08]) or
in the trials of more versus less statin (cancer incidence: 1466 [1.6% py] vs 1472 [1.6% py], RR 1.00 [95% CI 0.93–1.07]; cancer
mortality: 447 [0.5% py] versus 481 [0.5% py], RR 0.93 [95% CI 0.82–1.06]). Moreover, there was no evidence of any effect of
reducing LDL-C with statin therapy on cancer incidence or mortality at any of 23 individual categories of sites, with
increasing years of treatment, for any individual statin, or in any given subgroup. In particular, among individuals with low
baseline LDL-C (,2 mmol/L), there was no evidence that further LDL-C reduction (from about 1.7 to 1.3 mmol/L) increased
cancer risk (381 [1.6% py] versus 408 [1.7% py]; RR 0.92 [99% CI 0.76–1.10]).
Conclusions: In 27 randomised trials, a median of five years of statin therapy had no effect on the incidence of, or mortality
from, any type of cancer (or the aggregate of all cancer).
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Introduction
Randomised trials have shown that lowering low density
lipoprotein (LDL) cholesterol with a statin substantially reduces
the risk of major vascular events in a wide range of people [1], and
that further reductions in LDL cholesterol with more intensive
statin regimens produce further reductions in risk [2]. Statins are
able to lower LDL cholesterol to well below 2 mmol/L (80 mg/
dL) in many individuals, and LDL cholesterol concentrations as
low as this have been associated with an excess risk of cancer in
observational cohort studies [3]. Such associations have generally
been attributed to reverse causality arising from the tendency for
undetected cancers to lower LDL cholesterol [4;5]. The
availability of a large number of cancers in randomised trials of
statins now allow an unbiased assessment of whether reducing
LDL cholesterol with a statin causes cancer.
Although several published tabular meta-analyses of rando-
mised trials involving large numbers of cancers indicate that
standard statin regimens do not increase the aggregate risk of any
cancer over a period of around 4–5 years [6–9], such analyses are
unable to address concerns that lowering LDL cholesterol with a
statin might increase the risk of particular types of cancer. This
possibility had originally been raised by the results of individual
statin trials. For example, apparent excesses of gastrointestinal
cancer in the PROSPER trial [10] and breast cancer in the CARE
trial [11] generated considerable concern about the safety of
statins, despite a lack of corroborating evidence from other trials
[1]. Moreover, because patients in PROSPER were aged 70 or
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over, it was suggested that there might be an excess risk of cancer
among elderly people.
The Cholesterol Treatment Trialists’ (CTT) Collaboration has
recently reported analyses of the effects on major clinical outcomes
of further reductions in LDL cholesterol resulting from more
intensive statin regimens, and updated analyses of the effects of
standard statin regimens [2]. That meta-analysis concluded that
there was no overall evidence of any excess risk of cancer, or of
cancer mortality, associated with statin therapy. However, there is
a need for a more detailed assessment of specific types of cancer to
determine whether lowering LDL cholesterol with statins might
increase or decrease the risk of various cancers, as well as a need
for a more detailed assessment of whether lowering LDL
cholesterol to very low concentrations might increase the risk of
cancer. The present report, which includes individual patient data
on over 10,000 cancers among 175 000 participants in 27 statin
trials (including one trial not available in the previous analysis [12]
and 5 trials involving assessment of more-intensive LDL-lowering
therapy [13–17]) aims to provide such an assessment.
Methods
The methods of the Cholesterol Treatment Trialists’ Collabo-
ration have been described in detail previously [1;2;18]. Trials
were eligible for inclusion if: (i) the main effect of the intervention
was to lower LDL cholesterol; (ii) no other differences in risk factor
modification were intended; and (iii) at least 1000 participants
were to be recruited with at least 2 years’ treatment duration [2].
Each trial supplied individual patient data which were checked
centrally, recoded into a standard format for analysis, summarized
and verified for accuracy by the trialists.
The current analyses are of the incidence of cancer and of
death from cancer. Cancers were coded using the 9th revision of
the International Classification of Disease (ICD-9), and
subdivided into 23 detailed and 7 broad categories of sites
(Table S1): gastrointestinal (ICD9 140-159); genitourinary (179–
189); respiratory (160–163; 165); female breast (174), haemato-
logical (200–208), melanoma (172); and other specified or
unspecified sites (other codes in ICD-9 140–209). Nonfatal non-
melanoma skin cancers (173), benign neoplasms (210–229),
cancers in situ (230–234) and neoplasms of uncertain (235–238)
or unspecified (239) nature were excluded, as were nonfatal
cancers known to be recurrences of primary tumours diagnosed
prior to randomization and deaths from such recurrences.
(During the detailed coding process undertaken for these
analyses, minor corrections to previously published results [2]
were made for several of the trials.) The main planned analyses
were the effects of statin therapy on specific categories of
primary cancers, and on cancer incidence (and cancer death)
subdivided by year of follow-up, baseline LDL cholesterol, age,
sex and other baseline characteristics.
Statistical Methods
Analyses were to include all randomised patients irrespective of
whether they received their allocated treatment (‘‘intention-to-
treat’’). The primary meta-analyses were of the effects on cancer
event rates in each trial calculated as the logrank (o–e) and its
variance (v) for first events [2]. Analyses were performed both
weighted and unweighted for the absolute LDL cholesterol
difference in each trial at one year (d mmol/L) [2]. In a meta-
analysis of several trials, the log of the rate ratio per mmol/L (log
RR) is calculated as S/V with variance 1/V (and hence with 95%
CI of S/V61?96/!V), where S is the sum over all trials of d (o–e)
and V is the sum over all trials of d2v. (For unweighted analyses, d
is omitted from these formulae.) In subgroup analyses by baseline
LDL cholesterol concentration, the relevant baseline lipid values in
the trials comparing more versus less intensive statin therapy are
those achieved on the less intensive regimen. However, in 3 of
these trials [13;15;16], statin therapy was stopped before
randomization, so the values at randomization (i.e. off statin
treatment) tend to be overestimates of the relevant values. The
relevant baseline values for these 3 trials were therefore estimated
by multiplying the values at randomization by the mean
proportional reduction in LDL cholesterol observed at one year
among those allocated the less intensive regimen. Proportional risk
reductions in different subgroups were compared by standard x2
tests for heterogeneity or, where appropriate, trend. To help allow
for multiple subdivisions, only summary rate ratios (indicated by
open diamonds in figures) have 95% confidence intervals (CIs); all
other rate ratios have 99% CIs. Analyses were done using SAS
version 9.2 (SAS institute, Cary) and R version 2.11.1 (www.R-
project.org)
Results
Individual participant data were available from 27 trials of statin
therapy involving 174 149 participants (22 trials of statin versus
control [including one trial, CORONA [12], not previously
available for the second analysis cycle [2]] and 5 trials of more
versus less statin) (Table 1). (Individual participant data were
unavailable for these analyses from just 2 eligible trials involving
6331 participants: SPARCL [19], and GREACE [20].) For the
meta-analyses of statin versus control, the mean baseline LDL
cholesterol was 3.70 mmol/L, the mean LDL cholesterol difference
at one year was 1.08 mmol/L, and the median follow-up duration
among survivors was 4.8 years. For the meta-analyses of more
versus less intensive statin therapy, the weighted mean baseline LDL
cholesterol was 2.53 mmol/L, the weighted mean LDL cholesterol
difference at one year was 0.51 mmol/L, and the weighted median
follow-up duration among survivors was 5.1 years.
Cancers diagnosed after randomization
First cancers after randomization were recorded in the 22 trials
of statin versus control among 3755 (1.4% per year [py]) of 67 258
participants allocated statin therapy versus 3738 (1.4% py) of 67
279 allocated control, corresponding to a rate ratio of 1.00 (95%
CI 0.96–1.05), or an LDL-weighted rate ratio of 1.00 (95% CI
0.96–1.04) per 1 mmol/L LDL cholesterol reduction (Figure 1). In
the 5 trials of more versus less intensive statin therapy, first cancers
after randomization were recorded among 1466 (1.6% py) of 19
829 participants allocated more intensive versus 1472 (1.6% py) of
19 783 allocated less intensive therapy (Figure 1), corresponding to
a rate ratio (RR) of 1.00 (95% CI 0.93–1.07), which was equivalent
to an LDL-weighted rate ratio of 1.02 (95% CI 0.89–1.18) per
1 mmol/L LDL cholesterol reduction (Figure 1). Taking all 27
trials together, there was no evidence that lowering LDL
cholesterol increased the overall incidence of cancer (RR 1.00,
95% CI 0.96–1.04).
Likewise, there was no evidence of any excess in newly
diagnosed cancers that resulted in death in either type of trial
(Figure 2). Twenty one of the 22 trials of statin versus control
provided information on cancer mortality. In these trials, 1365
patients allocated statin versus 1358 patients allocated control died
from cancer (RR 1.00 [95% CI 0.93–1.08], or an LDL-weighted
rate ratio of 1.00 [95% CI 0.93–1.07] per 1 mmol/L LDL
cholesterol reduction), while in the 5 trials of more versus less
intensive statin therapy, 447 patients allocated more intensive
versus 481 patients allocated less intensive therapy died from
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Table 1. Baseline characteristics and eligibility criteria of participating trials.
Number
of
patients
Treatment
comparison
(mg per day)
Median
follow-up
in survivors
(years)*
Mean
age
(years)
Baseline
LDL-C
(mmol/L)
Prior
CHD
(%)**
Other
vascular
disease
(%){
No prior
vascular
disease
(%)
Women
(%)
LDL-C
difference
at 1 year
(mmol/L)
Statin vs. control
SSSS 4,444 S20-40 vs. placebo 5.4 59 4.88 4,444 (100%) 126 (3%) 0 (0%) 827 (19%) 21.77
WOSCOPS 6,595 P40 vs. placebo 4.8 55 4.96 338 (5%) 193 (3%) 6,096 (92%) 0 (0%) 21.07
CARE 4,159 P40 vs. placebo 5.0 59 3.58 4,159 (100%) 0 (0%) 0 (0%) 576 (14%) 21.03
Post CABG 1,351 L40-80 vs. L2.5-5 4.3 61 4.02 1,351 (100%) 37 (3%) 0 (0%) 102 (8%) 21.07
AFCAPS/TexCaps 6,605 L20-40 vs. placebo 5.2 58 3.89 10 (,1%) 9 (0%) 6,586(.99%) 997 (15%) 20.94
LIPID 9,014 P40 vs. placebo 6.0 61 3.88 9,014 (100%) 905 (10%) 0 (0%) 1,516 (17%) 21.03
GISSI-P 4,271 P20 vs. no treatment 2.0 59 3.92 4,271 (100%) 179 (4%) 0 (0%) 587 (14%) 20.35
LIPS 1,677 F80 vs. placebo 3.9 60 3.42 1,677 (100%) 142 (8%) 0 (0%) 271 (16%) 20.92
HPS 20,536 S40 vs. placebo 5.4 63 3.38 13,386 (65%) 8,865 (43%) 3,161 (15%) 5,082 (25%) 21.29
PROSPER 5,804 P40 vs. placebo 3.3 75 3.79 1,881 (32%) 1,026 (18%) 3,254 (56%) 3,000 (52%) 21.04
ALLHAT-LLT 10,355 P40 vs. usual care 4.9 67 3.76 1,188 (11%) 1,788 (17%) 8,037 (78%) 5,051 (49%) 20.54
ASCOT-LLA 10,305 A10 vs. placebo 3.3 63 3.44 15 (,1%) 1,435 (14%) 8,860 (86%) 1,942 (19%) 21.07
ALERT 2,102 F40 vs. placebo 5.5 50 4.14 400 (19%) 241 (11%) 1,702 (81%) 715 (34%) 20.84
CARDS 2,838 A10 vs. placebo 4.1 62 3.03 9 (,1%) 97 (3%) 2,738 (96%) 909 (32%) 21.14
ALLIANCE 2,442 A10-80 vs. usual care 4.7 61 3.80 2,442 (100%) 162 (7%) 0 (0%) 434 (18%) 21.16
4D 1,255 A20 vs. placebo 4.0 66 3.25 630 (50%) 666 (53%) 344 (27%) 578 (46%) 20.89
ASPEN 2,410 A10 vs. placebo 4.0 61 2.93 578 (24%) 302 (13%) 1,663 (69%) 811 (34%) 20.99
MEGA { { 8,214 P10-20 vs. usual care 5.0 58 4.05 42 (,1%) 53 (1%) 8,119 (99%) 5,547 (68%) 20.67
JUPITER 17,802 R20 vs. placebo 2.0 66 2.70 0 (0%) 0 (0%) 17,802 (100%) 6,801 (38%) 21.09
GISSI-HF 4,574 R10 vs. placebo 4.2 67 3.06 1,797 (39%) 4,574 (100%) 0 (0%) 1,032 (23%) 20.92
AURORA 2,773 R10 vs. placebo 4.6 64 2.58 659 (24%) 743 (27%) 1,663 (60%) 1,050 (38%) 20.99
CORONA 5,011 R10 vs. placebo 3.0 73 3.55 4,377 (87%) 5,011 (100%) 0 (0%) 1,180 (24%) 21.19
Subtotal (22 trials) 134,537 - 4.8|| 63|| 3.70|| 52,668
(39%)
26,554
(20%)
70,025
(52%)
39,008
(29%)
-1.08||
More vs. less statin
PROVE-IT 4,162 A80 vs. P40 2.1 58 2.621 4,162 (100%) 328 (8%) 0 (0%) 911 (22%) 20.65
A to Z 4,497 S40 then S80 vs.
placebo then S20
2.0 60 2.091 4,497 (100%) 479 (11%) 0 (0%) 1,100 (24%) 20.30
TNT 10,001 A80 vs. A10 5.0 61 2.52 10,001 (100%) 1,537 (15%) 0 (0%) 1,902 (19%) 20.62
IDEAL 8,888 A40-80 vs. S20-40 4.8 62 2.641 8,888 (100%) 971 (11%) 0 (0%) 1,702 (19%) 20.55
SEARCH 12,064 S80 vs. S20 7.0 64 2.50 12,064 (100%) 1,062 (9%) 0 (0%) 2,052 (17%) 20.39
Subtotal (5 trials) 39,612 - 5.1|| 62|| 2.53|| 39,612
(100%)
4,377
(11%)
0 (0%) 7,667
(19%)
-0.51||
Total (27 trials) 174,149 - 4.9|| 63|| - 92,280
(53%)
30,931
(18%)
70,025
(40%)
46,675
(27%)
-
Trials are ordered by their date of publication. A = atorvastatin. F = fluvastatin. L = lovastatin. P = pravastatin. R = rosuvastatin. S = simvastatin. LDL-C = LDL cholesterol.
CHD= coronary heart disease. 4D=Die Deutsche Diabetes Dialyse Studie. A to Z =Aggrastat to Zocor. AFCAPS/TexCAPS =Air Force/Texas Coronary Atherosclerosis
Prevention Study. ALERT =Assessment of Lescol in Renal Transplantation. ALLHAT-LLT =Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
ALLIANCE =Aggressive Lipid-Lowering Initiation Abates New Cardiac Events. ASCOT-LLA=Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm.
ASPEN=Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus. AURORA=A Study to Evaluate the Use of
Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events. CARDS =Collaborative Atorvastatin Diabetes Study.
CARE = Cholesterol And Recurrent Events. GISSI-HF =Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza cardiac. GISSI–P =Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto Miocardico. HPS =Heart Protection Study. IDEAL = Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.
JUPITER = Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study group. LIPID= Long–term Intervention with Pravastatin in
Ischaemic Disease. LIPS = Lescol Intervention Prevention Study. MEGA=Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study
Group. Post-CABG= Post-Coronary Artery Bypass Graft. PROSPER = PROspective Study of Pravastatin in the Elderly at Risk. PROVE-IT = Pravastatin or Atorvastatin
Evaluation and Infection Therapy. SEARCH= Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine. SSSS = Scandinavian Simvastatin
Survival Study. TNT= Treating to New Targets. WOSCOPS =West of Scotland Coronary Prevention Study.
*Estimated with standard Kaplan-Meier methods, with patients censored at their date of death.
**History of MI or other symptomatic CHD.
{History of intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, peripheral artery disease or heart failure (if known).
{{Includes 382 randomised patients who were excluded from the trialists’ primary publication.
|| Median follow–up, and mean age, baseline LDL-C and LDL-C difference at 1 year are weighted by the trial–specific variances of the observed logrank (o–e) statistic for
major vascular events.
1These three trials did not have active run–in periods; the values shown are the estimated on-treatment LDL cholesterol levels in the standard statin group.
doi:10.1371/journal.pone.0029849.t001
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cancer (RR 0.93 [95% CI 0.82–1.06], which was equivalent to an
LDL-weighted rate ratio of 0.88 [95% CI 0.67–1.15] per 1 mmol/
L LDL cholesterol reduction). Taking all trials together, there was
no evidence that lowering LDL cholesterol increased cancer
mortality (rate ratio 0.98 [95% CI 0.92–1.05]).
Since there was no significant heterogeneity among the results
of the trials for either cancer incidence (Figure 1) or cancer
mortality (Figure 2), and since the results weighted for LDL
cholesterol differences between studies yielded virtually identical
results to the unweighted analyses, subsequent analyses focus on
the unweighted results seen in all 27 trials (separate analyses of the
trials of statin versus control and the trials of more versus less statin
can be found in the supporting information).
Anatomical site of cancer
Although there was no evidence of an increase in the overall
incidence of any cancer within the 27 trials of statin therapy, such
an analysis would be insensitive to an increase in just one or a few
types of cancer. There was, however, no evidence of an increased
risk of cancer at any of 23 individual categories of sites, either in
the 27 trials considered together (table 2), or separately in the 22
trials of statin versus control or the 5 trials of more versus less
intensive statin therapy (Table S2). Similarly, there was no
evidence of any increased risk of death from cancer at any
individual site (table 2 and Table S2). (Note: The apparent
reductions in liver cancer incidence [7 vs 18; nominal p = 0.05]
and in deaths due to cancers from other known sites [5 vs 16;
nominal p = 0.03] among the 5 trials of more versus less intensive
statin therapy [Table S2] were not significant after adjustment for
multiplicity.)
Incidence of cancer over time
If lowering LDL cholesterol were a cause of cancer then it might
be anticipated that the rate ratio for first cancers in each year of
follow-up would tend to increase over time. There was, however,
no evidence of a trend towards an increasing relative risk of a first
cancer in all 27 trials (trend p=0.57, Figure 3), or separately in the
22 trials of statin versus control or the 5 trials of more versus less
statin (Figure S1). Similarly, there was no evidence of any such
trends in analogous analyses of cancer mortality (trend p=0.64 for
all 27 trials: Figure 3 and Figure S2).
LDL cholesterol before treatment
If low LDL cholesterol concentration is a cause of cancer then
one might expect to see a trend towards larger rate ratios among
those with lower LDL cholesterol before treatment. However, if
Figure 1. Effects of statin therapy on cancer incidence in each study. In the left panel, unweighted rate ratios (RRs) are plotted for each trial
of the comparison of first event rates between randomly allocated treatment groups, along with their 99% confidence intervals (CIs). Trials are
ordered according to the absolute reduction in LDL cholesterol at 1 year within each type of trial comparison (statin versus control and more versus
less statin). In the right panel, rate ratios are weighted per 1 mmol/L LDL cholesterol difference at 1 year. Totals and subtotals, together with their
95% CIs, are indicated by open diamonds.
doi:10.1371/journal.pone.0029849.g001
IPD Meta-Analysis of Effect of Statins on Cancer
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29849
anything, there were fewer cancers among participants with lower
baseline LDL cholesterol who were allocated statin or more
intensive statin regimens (trend p= 0.07; Figure 4 and Figure S3).
For instance, among individuals with baseline LDL cholesterol less
than 2.00 mmol/L on the control or less intensive statin regimen,
further LDL cholesterol reduction with a statin or more intensive
statin regimen (from about 1.7 mmol/L to 1.3 mmol/L) was
associated with a non-significant 8% reduction in cancer incidence
(381 [1.6% py] versus 408 [1.7% py]; RR=0.92, 99% CI 0.76–
1.10) (Figure 4). In analyses of deaths due to cancer, a similar
pattern was observed, with, if anything, smaller RRs observed
among those with lower baseline LDL cholesterol levels (trend
p= 0.008 for all 27 trials together; Figure 4 and Figure S4). These
suggested trends were non-significant after adjustment for multiple
testing however.
Age, sex and other baseline characteristics
The PROSPER trial of pravastatin versus placebo conducted
among people aged 70 or over had previously reported an excess
risk of gastrointestinal cancer among statin allocated patients
[10]. But, in the present meta-analysis, there was no evidence for
an increased risk of any cancer among older people (Figure 5),
even among those aged $75 at baseline (721 [2.6% py] statin/
more statin versus 689 [2.4%] control/less statin; RR=1.05,
99% CI 0.92–1.21) (Figure 5 and Figure S5). There was also no
significant trend towards increasing rate ratios with older age
(trend p= 0.34: Figure 5). Similarly, in analyses of cancer
mortality, there was no evidence of any excess risk of death
from cancer in older people and no evidence of an increasing
trend in the rate ratio for cancer death with increasing age
(Figure 5 and Figure S6). Rate ratios were also similar among
men and women for both cancer incidence (heterogeneity
p = 0.08; Figure 5) and for death from cancer (heterogeneity
p = 0.66; Figure 5), and were also similar across a range of other
baseline characteristics (Figures S7 and S8). (Note: The apparent
trend towards a cancer excess among people with diabetes
[heterogeneity p-value = 0.009: Figure S7] was not significant
after adjustment for multiple testing.)
Type of statin
In the 22 trials that compared statin therapy versus control, rate
ratios for cancer incidence and death from cancer were similar
irrespective of type of statin (Figures S9 and S10). In particular,
there was no evidence that rate ratios differed between statins that
are hydrophilic (pravastatin and rosuvastatin: cancer incidence
RR 1.02 [95% CI 0.96 to 1.08]; cancer mortality RR 0.99 [95%
CI 0.89 to 1.09]) and statins that are mostly lipophilic
(atorvastatin, fluvastatin, lovastatin, simvastatin: cancer incidence
RR 0.98 [95% CI 0.92 to 1.05]; cancer mortality RR 1.01 [95%
CI 0.91 to 1.13]).
Figure 2. Effects of statin therapy on cancer mortality in each study. Symbols and conventions as in Figure 1. Deaths from cancers known to
have been first diagnosed prior to randomization are excluded.
doi:10.1371/journal.pone.0029849.g002
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Discussion
This meta-analysis of individual participant data from rando-
mised trials provides reassuring evidence that reducing LDL
cholesterol with statin therapy during a treatment period of about
five years is not associated with an increased risk of developing a
new cancer or of dying from cancer. In particular, it did not
indicate any excess of particular types of cancer, or excesses of
cancer with more prolonged or more intensive lowering of LDL
cholesterol, even among older people. Nor was there any evidence
that statin therapy reduces the risk of any particular type of cancer.
The findings of this meta-analysis are robust since they are
based on over 10,000 cases of cancer and over 3500 deaths from
cancer among 175,000 randomised patients. In addition, because
they are derived from individual patient data, they provide a much
more reliable test of the possible effects on cancer of lowering LDL
cholesterol with a statin than has previously been possible from
tabular meta-analyses. While individual patient data were not
available from 2 eligible trials [19;20], their inclusion would have
had no material effect on the findings: in one of those trials, 57
atorvastatin-allocated patients and 53 allocated placebo died from
cancer (but the incidence of cancer was not reported) [19], while
the other trial did not report the number of fatal or incident
cancers but it included only 1600 patients [20].
Previously, it had been reported from observational studies in
the general population [3] and from non-randomised analyses
within statin trials [21;22], that lower levels of LDL cholesterol
were associated with higher risks of cancer. The present meta-
Table 2. Cancer incidence and cancer mortality in all 27 trials, by site.
Cancer incidence Cancer mortality*
Statin/More
(n=87087)
Control/Less
(n =87062) p value
Statin/More
(n=87087)
Control/Less
(n =87062) p value
Total follow-up (person years) 359581 358764 367936 367146
Site of Cancer
Gastrointestinal 1214 1245 0.49 503 507 0.86
Lip, mouth or pharynx 68 66 0.95 10 15 0.41
Oesophageal 81 83 0.92 45 55 0.36
Stomach 118 124 0.75 64 54 0.43
Large bowel or intestine 549 567 0.57 148 165 0.34
Liver 42 51 0.39 28 32 0.68
Gall bladder or bile-ducts 26 30 0.67 22 20 0.89
Pancreas 106 96 0.54 82 71 0.44
Other gastrointestinal 224 228 0.84 104 95 0.58
Genitourinary 1644 1676 0.52 222 238 0.45
Prostate 923 954 0.44 104 107 0.87
Penis/Scrotum 140 123 0.34 4 3 1.00
Uterus 57 60 0.86 7 8 0.99
Ovarian 35 36 1.00 14 16 0.86
Other genitourinary 17 14 0.73 5 2 0.45
Bladder 315 331 0.53 49 64 0.18
Kidney 157 158 0.97 39 38 1.00
Respiratory 845 847 0.93 553 584 0.34
Trachea/Lung 709 705 0.98 462 495 0.27
Other respiratory 136 142 0.74 91 89 0.95
Female breast 273 244 0.22 24 17 0.35
Haematological 313 301 0.70 118 120 0.92
Melanoma 160 145 0.45 17 19 0.86
Other/unspecified 772 752 0.65 375 354 0.50
Neurological 67 57 0.44 55 45 0.39
Other known site 219 199 0.34 94 81 0.36
Unspecified 486 496 0.74 226 228 0.91
All cancer 5221 5210 0.96 1812 1839 0.57
Excluding death from cancers known to have been first diagnosed prior to randomisation. ICD-9 cancer codes: Gastrointestinal (140–159); Lip, mouth or pharynx (140–
149); Oesophageal (150); Stomach (151); Large bowel or intestine (152–154); Liver (155); Gall bladder or bile-ducts (156); Pancreas (157); Other gastrointestinal (158,159);
Genitourinary (179–189); Prostate (185); Penis/Scrotum (187); Uterus (179,180,182); Ovarian (183); Other genitourinary (181,184,186); Bladder (188); Kidney (189);
Respiratory (160–163,165); Trachea/Lung (162); Other respiratory (160,161,163,165); Female breast (174); Haematological (200–208); Melanoma (172); Other/unspecified
([Neurological (191,192); Other known site (164,170,171,175,176,190,193–195); Unspecified (196–199, 209)]); All cancer (140–209 excluding 173). If the ICD9 cause of
death was 173 or 210–239 then both cancer incidence and cancer death was coded as unknown cancer. P-values are continuity corrected.
doi:10.1371/journal.pone.0029849.t002
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Figure 3. Effects of statin therapy on cancer incidence and mortality, by duration of treatment. Symbols and conventions as in Figure 1.
doi:10.1371/journal.pone.0029849.g003
Figure 4. Effects of statin therapy on cancer incidence and mortality, by baseline LDL cholesterol. Symbols and conventions as in
Figure 1. To convert from mmol/L to mg/dL divide by 0.02586.
doi:10.1371/journal.pone.0029849.g004
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analysis of randomised evidence avoids the biases inherent in such
non-randomised comparisons. Moreover, it involves large num-
bers of individuals in trials of more intensive statin therapy in
whom LDL cholesterol was reduced to low levels. Consequently it
is able to provide reliable evidence that there is no material cancer
excess even when LDL cholesterol is reduced to about 1.3 mmol/
L.
The present meta-analysis also provides reassurance that
excesses in particular types of cancer observed in some of the
individual trials were likely to have been due to the play of chance
[23]. For example, the excess of breast cancer observed among
women randomly allocated to pravastatin in the CARE trial (9
pravastatin versus 0 placebo; p = 0.004) [11], was not supported by
the much larger number of female breast cancer cases in the other
26 trials (264 [1.1%] statin/more versus 244 [1.1%] control/less;
p = 0.4). Similarly, the excess of gastrointestinal cancer originally
reported in the PROSPER trial (65 pravastatin versus 45 placebo;
p = 0.05) [10] was not supported by the results in the other trials
shown here (1140 [1.4%] statin/more versus 1195 [1.4%]
control/less; p = 0.2). It has also been suggested, based on
observational and preclinical studies, that statins may prevent
some types of cancer (such as prostate [24], oesophageal [25],
colorectal [26]). But, again, this meta-analysis provides no
evidence in support of such effects, at least within about five
years of starting treatment.
An effect of lowering cholesterol on cancer risk might be missed
if the latency period is substantially longer than the treatment
period studied in these trials. There was, however, no suggestion in
the meta-analysis of an increasing trend in the relative risk of
cancer with increasing duration of treatment for up to about 6
years. Nor was there any suggestion in several of the individual
trials that cancer risk increased during prolonged follow-up for up
to a decade after the scheduled statin treatment period [27-30].
For example, in the WOSCOPS trial, no differences in cancer
incidence were seen between the patients originally allocated
pravastatin or placebo for 5 years during the subsequent 10 years
[27] (reinforcing the results of 2 year post-trial follow-up in the
LIPID trial [28]). Similarly, in the 4S trial, no significant
differences in cancer incidence were seen between the patients
allocated simvastatin or placebo for 5 years during the subsequent
5 years of follow-up [29]. More recently, 5-year post-trial follow-
up of the 20,000 patients in the Heart Protection Study found no
increased cancer risk associated with 5 years of prior treatment
with simvastatin [30].
Figure 5. Effects of statin therapy on cancer incidence and mortality, by age and sex. Symbols and conventions as in Figure 1.
doi:10.1371/journal.pone.0029849.g005
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Conclusion
It has been shown previously that reducing LDL cholesterol
with a statin reduces the risk of major vascular events by about
one-fifth for each 1 mmol/L reduction in LDL cholesterol, and
that further reductions in LDL cholesterol with more intensive
statin therapy produce further reductions in risk, even among
patients who already have LDL cholesterol levels below 2 mmol/L
[2]. The present report now demonstrates clearly that such
reductions in LDL cholesterol do not increase the rate of cancer or
cancer death, overall or at any particular site, during a treatment
period of about 5 years (and more prolonged follow-up in some of
the trials does not indicate any later excess) even among older
individuals or those who have their cholesterol levels reduced to
very low levels. These findings provide considerable reassurance
about the safety of using more intensive statin regimens to lower
LDL cholesterol levels substantially in patients who remain at high
risk of major vascular events.
Supporting Information
Figure S1 Effects of statin therapy on cancer incidence, by
duration of treatment.
(PDF)
Figure S2 Effects of statin therapy on cancer mortality, by
duration of treatment.
(PDF)
Figure S3 Effects of statin therapy on cancer incidence, by
baseline LDL cholesterol.
(PDF)
Figure S4 Effects of statin therapy on cancer mortality, by
baseline LDL cholesterol.
(PDF)
Figure S5 Effects of statin therapy on cancer incidence, by age
and sex.
(PDF)
Figure S6 Effects of statin therapy on cancer mortality, by age
and sex.
(PDF)
Figure S7 Effects of statin therapy on cancer incidence, by other
baseline characteristics.
(PDF)
Figure S8 Effects of statin therapy on cancer mortality, by other
baseline characteristics.
(PDF)
Figure S9 Effects of statin therapy on cancer incidence in 22
statin vs. control trials, by type of statin.
(PDF)
Figure S10 Effects of statin therapy on cancer mortality in 22
statin vs. control trials, by type of statin.
(PDF)
Table S1 Number of patients with a report of cancer (number of
cancer deaths), by site and trial.
(PDF)
Table S2 Cancer incidence and cancer mortality by site, in 22
trials of statin vs. control and 5 trials of more vs. less statin.
(PDF)
Acknowledgments
Writing Committee
Jonathan R. Emberson1., Patricia M. Kearney2., Lisa Blackwell1,
Connie Newman3, Christina Reith1, Neeraj Bhala1, Lisa Holland1,
Richard Peto1, Anthony Keech4, Rory Collins1, John Simes4, Colin
Baigent1
1 Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU),
Oxford, United Kingdom,
2 Department of Epidemiology and Public Health, University College
Cork, Cork, Ireland,
3 Division of Endocrinology and Metabolism, New York University
Medical Center, New York, New York, United States of America,
4 National Health and Medical Research Council (NHMRC) Clinical
Trial Centre, University of Sydney, Sydney, New South Wales, Australia
. These authors contributed equally to this work.
Current membership of the CTT Collaboration
Contributing trials: A to Z trial (phase Z) J de Lemos, E Braunwald, M
Blazing, S Murphy; AFCAPS/TEXCAPS (AirForce/Texas Coronary
Atherosclerosis Prevention Study) J R Downs, A Gotto, M Clearfield;
ALERT (Assessment of Lescol in Transplantation) H Holdaas; ALLHAT
(Antihypertensive Lipid Lowering Heart Attack Trial) D Gordon, B Davis;
ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac
Events) M Koren; ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial)
B Dahlof, N Poulter, P Sever; ASPEN (Atorvastatin Study for the
prevention of coronary heart disease endpoints in noninsulin dependent
diabetes mellitus) R H Knopp (deceased); AURORA (A study to evaluate
the Use of Rosuvastatin in subjects On Regular haemodialysis: an
Assessment of survival and cardiovascular events) B Fellstro¨m, H Holdaas,
A Jardine, R Schmieder, F Zannad; BIP (Bezafibrate Infarction Prevention
Study), U Goldbourt, E Kaplinsky; CARDS (Collaborative Atorvastatin
Diabetes Study) H M Colhoun, D J Betteridge, P N Durrington, G A
Hitman, J Fuller, A Neil; 4D (Die Deutsche Diabetes Dialyse study) C
Wanner, V Krane; CARE (Cholesterol And Recurrent Events Study) F
Sacks, L Moye´, M Pfeffer; C M Hawkins, E Braunwald; CORONA
(Rosuvastatin in Older Patients with Systolic Heart Failure) J Kjekshus, H
Wedel, J Wikstrand; GISSI (Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto miocardico)–Heart Failure L Tavazzi, A
Maggioni; GISSI–Prevention R Marchioli, G Tognoni, M G Franzosi, A
Maggioni; HPS (Heart Protection Study) R Collins, J Armitage, A Keech,
S Parish, R Peto, P Sleight; IDEAL (Incremental Decrease in Endpoints
through Aggressive Lipid-lowering) T R Pedersen; JUPITER (Justification
for the Use of Statins in Prevention: an International Trial Evaluating
Rosuvastatin) P M Ridker; LIPID (Long-term Intervention with Prava-
statin in Ischaemic Disease) J Simes, A Keech, S MacMahon, I Marschner,
A Tonkin, J Shaw; LIPS (Lescol Intervention Prevention Study) P W
Serruys; MEGA (Management of Elevated cholesterol in the primary
prevention Group of Adult Japanese) H Nakamura; Post-CABG (Post-
Coronary Artery Bypass Graft Study) G Knatterud; PPP (Pravastatin
Pooling Project) C Furberg, R Byington; PROSPER (Prospective Study of
Pravastatin in the Elderly at Risk) P Macfarlane, S Cobbe, I Ford, M
Murphy, G J Blauw, C Packard, J Shepherd; 4S (Scandinavian Simvastatin
Survival Study) J Kjekshus, T Pedersen, L Wilhelmsen; PROVE-IT
(Pravastatin or Atorvastatin Evaluation and Infection Therapy) E
Braunwald, C Cannon, S Murphy; SEARCH (Study of Effectiveness of
Additional Reductions in Cholesterol and Homocysteine) R Collins, J
Armitage, L Bowman, S Parish, R Peto, P Sleight; TNT (Treating to New
Targets) J La Rosa; WOSCOPS (West of Scotland Coronary Prevention
Study) J Shepherd, S Cobbe, P Macfarlane, I Ford.
Other members: M Flather, J Kastelein, C Newman, C Shear, J Tobert,
J Varigos, H White, S Yusuf.
CTT secretariat: A Baxter, C Baigent, E H Barnes, N Bhala, L
Blackwell, G Buck, R Collins, J Emberson, W G Herrington, L E Holland,
P M Kearney, A Keech, A Kirby, D A Lewis, I Marschner, C Reith, J
Simes.
Observers: Bristol-Myers Squibb: M Mellies, M McGovern, J Barclay, R
Belder; Merck: Y Mitchell, T Musliner: Laboratoires Fournier: J-C
Ansquer; Bayer: M Llewellyn; Novartis Pharma: M Bortolini; AstraZeneca:
B Bryzinski; G Olsson, J Pears; Pfizer: D DeMicco.
IPD Meta-Analysis of Effect of Statins on Cancer
PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e29849
Author Contributions
Conceived and designed the experiments: RP AK RC JS CB. Performed
the experiments: RP AK RC JS CB. Analyzed the data: JE LB CB. Wrote
the paper: JE PK CN CB. Clinical coding: PK CR NB CB. Acquisition of
data: JE LB LH AK RC JS CB. Critical revision of manuscript for
important intellectual content: All authors.
References
1. Cholesterol Treatment Trialists Collaboration (2005) Efficacy and safety of
cholesterol-lowering treatment: prospective meta-analysis of data from 90,056
participants in 14 randomised trials of statins. Lancet 366: 1267–78.
2. Cholesterol Treatment Trialists Collaboration (2010) Efficacy and safety of more
intensive lowering of LDL cholesterol: meta-analysis of data from 170,000
participants in 26 randomised trials. Lancet 376: 1670–81.
3. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, et al. (1992) Report of the
Conference on Low Blood Cholesterol: Mortality Associations. Circulation 86:
1046–60.
4. Law MR, Thompson SG (1991) Low serum cholesterol and the risk of cancer:
an analysis of the published prospective studies. Cancer Causes Control 2:
253–61.
5. Sharp SJ, Pocock SJ (1997) Time trends in serum cholesterol before cancer
death. Epidemiology 8: 132–6.
6. Kuoppala J, Lamminpaa A, Pukkala E (2008) Statins and cancer: A systematic
review and meta-analysis. Eur J Cancer 44: 2122–32.
7. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and
cancer risk: a meta-analysis. JAMA 295: 74–80.
8. Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review
and meta analysis. Int J Cancer 120: 833–43.
9. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM (2007) Statins and the risk of
colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million
patients. J Clin Oncol 25: 3462–8.
10. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. (2002)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a
randomised controlled trial. Lancet 360: 1623–30.
11. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The
effect of pravastatin on coronary events after myocardial infarction in patients
with average cholesterol levels. Cholesterol and Recurrent Events Trial
investigators. N Engl J Med 335: 1001–9.
12. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JGF, et al. (2007)
Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 357:
2248–61.
13. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004)
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary
Syndromes. N Engl J Med 350: 1495–504.
14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive
Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease.
N Engl J Med 352: 1425–35.
15. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, et al.
(2005) High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary
Prevention After Myocardial Infarction: The IDEAL Study: A Randomized
Controlled Trial. JAMA 294: 2437–45.
16. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, et al. (2004) Early
Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute
Coronary Syndromes: Phase Z of the A to Z Trial. JAMA 292: 1307–16.
17. Study of the Effectiveness of Additional Reductions in Cholesterol and
Homocysteine (SEARCH) Collaborative Group (2010) Intensive lowering of
LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors
of myocardial infarction: a double-blind randomised trial. Lancet 376: 1658–69.
18. Cholesterol Treatment Trialists’ (CTT) Collaboration (1995) Protocol for a
prospective collaborative overview of all current and planned randomized trials
of cholesterol treatment regimens. Am J Cardiol 75: 1130–4.
19. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels
(SPARCL) Collaboration (2006) High-Dose Atorvastatin after Stroke or
Transient Ischemic Attack. N Engl J Med 355: 549–59.
20. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN,
et al. (2002) Treatment with atorvastatin to the National Cholesterol
Educational Program goal versus ‘usual’ care in secondary coronary heart
disease prevention. The GREek Atorvastatin and Coronary-heart-disease
Evaluation (GREACE) study. Curr Med Res Opin 18: 220–8.
21. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH (2008) Statins, Low-
Density Lipoprotein Cholesterol, and Risk of Cancer. J Am Coll Cardiol 52:
1141–7.
22. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH (2007) Effect of the
magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis,
and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50:
409–18.
23. Collins R, Armitage J (2002) High-risk elderly patients PROSPER from
cholesterol-lowering therapy. Lancet 360: 1618–9.
24. Solomon KR, Freeman MR (2008) Do the cholesterol-lowering properties of
statins affect cancer risk? Trends Endocrinol Metab 19: 113–21.
25. Hippisley-Cox J, Coupland C (2010) Unintended effects of statins in men and
women in England and Wales: population based cohort study using the
QResearch database. BMJ 340: c2197.
26. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, et al. (2005) Statins
and the risk of colorectal cancer. N Engl J Med 352: 2184–92.
27. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, et al. (2007) Long-
term follow-up of theWest of Scotland Coronary Prevention Study. N Engl J Med
357: 1477–86.
28. LIPID Study Group (2002) Long-term effectiveness and safety of pravastatin in
9014 patients with coronary heart disease and average cholesterol concentra-
tions: the LIPID trial follow-up. Lancet 359: 1379–87.
29. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, et al. (2004)
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian
Simvastatin Survival Study (4S). Lancet 364: 771–7.
30. Heart Protection Study Collaborative Group (2011) Effects on 11 year mortality
and morbidity of lowering LDL cholesterol with simvastatin for about 6 years in
20536 high-risk individuals. Lancet doi:10.1016/S0140-6736(11)61125-2.
IPD Meta-Analysis of Effect of Statins on Cancer
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e29849
